Trisomy 14 in acute myelogenous leukemia and myelodysplastic syndrome
Toze, C.L.; Barnett, M.J.; Naiman, S.C.; Horsman, D.E.
Blood 84(10 Suppl 1): 626A
1994
ISSN/ISBN: 0006-4971 Accession: 034080977
Full Text Article emailed within 1 workday: $29.90
Related References
Kurotaki, H.; Tsushima, Y.; Nagai, K.; Yagihashi, S. 1999: Apoptosis, bcl -2 Expression and p53 Accumulation in Myelodysplastic Syndrome, Myelodysplastic-Syndrome-Derived Acute Myelogenous Leukemia and de novo Acute Myelogenous Leukemia Acta Haematologica 102(3): 115-123Kurotaki, H.; Tsushima, Y.; Nagai, K.; Yagihashi, S. 2000: Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia Acta Haematologica 102(3): 115-123
Festuccia, M.; Deeg, H.J.; Gooley, T.A.; Baker, K.; Wood, B.L.; Fang, M.; Sandmaier, B.M.; Scott, B.L. 2016: Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 22(7): 1227-1233
Cortes, J.E.; Kantarjian, H.; O'Brien, S.; Keating, M.; Pierce, S.; Freireich, E.J.; Estey, E. 1995: Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes Leukemia 9(1): 115-117
Yamamoto, K.; Nagata, K.; Kida, A.; Hamaguchi, H.; Inagaki, K. 2002: Karyotypic conversion from trisomy 4 to trisomy 14 during the evolution of therapy-related myelodysplastic syndrome to acute myeloblastic leukemia Cancer Genetics and Cytogenetics 132(1): 83-84
Potter, V.T.; Krishnamurthy, P.; Barber, L.D.; Lim, Z.; Kenyon, M.; Ireland, R.M.; de Lavallade, H.; Dhouri, A.; Marsh, J.C.W.; Marcus, R.; Devereux, S.; Ho, A.; Pagliuca, A.; Mufti, G.J. 2014: Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 20(1): 111-117
Latagliata, R.; Petti, M.Concetta.; Fenu, S.; Mancini, M.; Spiriti, M.Antonietta.Aloe.; Breccia, M.; Brunetti, G.A.; Avvisati, G.; Lo Coco, F.; Mandelli, F. 2002: Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem Blood 99(3): 822-824
Garcia Manero, G.; Kantarjian, H.M.; Kornblau, S.; Estey, E. 2002: Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia Leukemia 16(9): 1888
Garcia-Manero, G.; Kantarjian, H.M.; Kornblau, S.; Estey, E. 2002: Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL) Leukemia 16(9): 1888
Rossbach, H.C.; Sutcliffe, M.J.; Chamizo, W.; Haag, M.M.; Grana, N.H.; Washington, K.R.; Barbosa, J.L. 1998: Pre-B acute lymphoblastic leukemia in a 3-year-old boy with pre-acute myelogenous leukemia myelodysplastic syndrome: cytogenetic evidence of common early progenitor cell ontogeny Journal of Pediatric Hematology/Oncology 20(4): 347-352
Verma, D.; O'Brien, S.; Thomas, D.; Faderl, S.; Koller, C.; Pierce, S.; Kebriaei, P.; Garcia-Manero, G.; Cortes, J.; Kantarjian, H.; Ravandi, F. 2009: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens Cancer 115(1): 101-106
Rosenfeld, C.; Kantarjian, H. 2001: Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies Leukemia and Lymphoma 41(5-6): 493-500
Rosenfeld, C.; Cheever, M.A.; Gaiger, A. 2003: WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies Leukemia 17(7): 1301-1312
Kaneko, Y.; Maseki, N.; Sakurai, M.; Shibuya, A.; Shinohara, T.; Fujimoto, T.; Kanno, H.; Nishikawa, A. 1989: Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis Leukemia 3(1): 36-41
Gross-King, M. 1997: For Acute Myelogenous Leukemia and Myelodysplastic Syndrome Cancer Control 4(5): 1-4
Matthews, D.C. 1998: Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome Leukemia 12(Suppl 1): S33-S36
Glassman, A.B.; Hayes, K.J. 2003: Translocation (11;16)(q23;p13) acute myelogenous leukemia and myelodysplastic syndrome Annals of Clinical and Laboratory Science 33(3): 285-288
Shih, L.Y.; Huang, C.F.; Lin, T.L.; Wu, J.H.; Wang, P.N.; Dunn, P.; Kuo, M.C.; Tang, T.C. 2005: Heterogeneous patterns of CEBPα mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia Clinical Cancer Research 11(5): 1821-1826
Lai, R.; Arber, D.A.; Brynes, R.K.; Chan, O.; Chang, K.L. 1999: Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature American Journal of Clinical Pathology 111(3): 373-378
Shih, L.-Y.; Huang, C.-F.; Lin, T.-L.; Wu, J.-H.; Wang, P.-N.; Dunn, P.; Kuo, M.-C.; Tang, T.-C. 2005: Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11(5): 1821-1826